The Switzerland-based pharmaceutical company has been trying to crack the weight-loss boom currently dominated by Eli Lilly ...

Amgen is a decently valued stock that has an excellent business and also gives investors a way to potentially gain exposure to a lucrative weight loss market.

A recent announcement by Eli Lilly suggests that the company understands the economic conundrum some patients face. Per a ...

Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...

On the heels of an FDA rejection for its chief rival Novo Nordisk, Eli Lilly is gaining ground in the race to bring a ...

Eli Lilly could be on its way to topping $1 trillion in market value. Meanwhile, Abbott launches its first over-the-counter ...

Nonprofit group the Obesity Action Coalition (OAC) is running a new challenge as part of its “Your Weight Matters” ...

Eli Lilly's new insulin data —Sanofi x Regeneron autoimmune drugs —Gilead's new AI partnership Get the full rundown here: ...

Novo Nordisk CEO Lars Jørgensen will testify about the high cost of Ozempic and Wegovy at an upcoming HELP Committee hearing on September 24th.

In fact, demand has been so high that it's been surpassing supply, forcing Lilly and rival Novo Nordisk to invest in ...

As Novo Nordisk A/S and Eli Lilly and Co. go head-to-head in the U.S. and Chinese glucagon-like peptide-1 receptor agonists ...

The highly anticipated new obesity pill shows the potential for greater and faster weight loss than Wegovy. There is a new ...